These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23075915)

  • 1. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
    Hammond KP; Wolfe P; Burton JR; Predhomme JA; Ellis CM; Ray ML; Bushman LR; Kiser JJ
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):67-73. PubMed ID: 23075915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
    Ramanathan S; Kakuda TN; Mack R; West S; Kearney BP
    Antivir Ther; 2008; 13(8):1011-7. PubMed ID: 19195326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
    Gutiérrez-Valencia A; Martin-Peña R; Torres-Cornejo A; Ruiz-Valderas R; Castillo-Ferrando JR; López-Cortés LF
    J Antimicrob Chemother; 2012 Mar; 67(3):681-4. PubMed ID: 22190606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
    Jackson A; D'Avolio A; Moyle G; Bonora S; Di Perri G; Else L; Simiele M; Singh GJ; Back D; Boffito M
    J Antimicrob Chemother; 2014 Jul; 69(7):1911-5. PubMed ID: 24610312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.
    Hulskotte EG; Bruce RD; Feng HP; Webster LR; Xuan F; Lin WH; O'Mara E; Wagner JA; Butterton JR
    Eur J Clin Pharmacol; 2015 Mar; 71(3):303-11. PubMed ID: 25666027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
    Mora-Peris B; Else L; Goldmeier D; Mears A; Weston R; Cooke G; Khoo S; Back D; Winston A
    J Antimicrob Chemother; 2015; 70(6):1812-5. PubMed ID: 25693997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
    de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
    J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
    Kakuda TN; Leopold L; Nijs S; Vandevoorde A; Crauwels HM; Bertelsen KM; Stevens M; Witek J; van Delft Y; Tomaka F; Hoetelmans RM
    J Clin Pharmacol; 2014 May; 54(5):563-73. PubMed ID: 25975423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Vanaken H; Bouche MP; Peeters M; Woodfall B; Hoetelmans RM
    Br J Clin Pharmacol; 2008 Oct; 66(4):508-16. PubMed ID: 18492125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.